Targeted therapies for Kirsten rat sarcoma (KRAS) G12C mutant metastatic non-small-cell lung cancers
C O'Leary, G Murphy, Y Yeung, M Tang, V Jain… - Cancers, 2023 - mdpi.com
Simple Summary Non-small-cell lung cancers (NSCLCs) are commonly diagnosed
malignancies with poor prognosis. Kirsten rat sarcoma virus (KRAS) mutations are often …
malignancies with poor prognosis. Kirsten rat sarcoma virus (KRAS) mutations are often …
Integrated decision-making in the treatment of colon-rectal cancer: the case of KRAS-mutated tumors
S Cherri, L Melocchi, L Gandolfi, G Rossi, A Zaniboni - Life, 2023 - mdpi.com
In recent years, precision medicine has taken an increasing place in various branches of
medical oncology, including colorectal cancer. Among the potentially relevant mutations for …
medical oncology, including colorectal cancer. Among the potentially relevant mutations for …
FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for …
A Behnke, A Cayre, G De Maglio… - Pathology and …, 2023 - por-journal.com
Accurate testing for epidermal growth factor receptor (EGFR) variants is essential for
informing treatment decisions in non-small cell lung cancer (NSCLC). Automated diagnostic …
informing treatment decisions in non-small cell lung cancer (NSCLC). Automated diagnostic …
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
K Suda, K Sakai, T Ohira, T Chikugo, T Satou… - Cancers, 2023 - mdpi.com
Simple Summary Genetic information is essential before starting the treatment of advanced-
stage non-small-cell lung cancer (NSCLC) and in the adjuvant setting (EGFR mutation …
stage non-small-cell lung cancer (NSCLC) and in the adjuvant setting (EGFR mutation …
Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing
GV George, H Liu, AN Jajosky, ZN Oltvai - Genes, 2024 - mdpi.com
BRAF mutation identification is important for the diagnosis and treatment of several tumor
types, both solid and hematologic. Rapid identification of BRAF mutations is required to …
types, both solid and hematologic. Rapid identification of BRAF mutations is required to …